Site Map
- Home
- About Us
- Adrenal Insufficiency
- Therapy
- FAQ
- Contact
- Links
- News
- News in English
- DuoCort Pharma’s Orphan Drug Plenadren® Granted European Marketing Authorization for Adrenal Insufficiency.
- DuoCort inks deal to sell Plenadren®
- Positive Opinion from CHMP for Plenadren®
- DuoCort Pharma and Clinigen sign agreement on named patient programme for Plenadren
- DuoCort Pharma and Recipharm start innovative collaboration
- Better quality of life with new orphan drug for Addison´s disease
- DuoCort seeks European market authorisation for orphan drug
- Article on DuoCort in European Life Science
- Maria Forss selected in Swedish Initiative for Women Board Members
- New chronotherapy for Addison´s disease
- Successful phase II/III trial of new therapy.
- P.U.L.S. further strengthens its project management team.
- DuoCort Gets Orphan Drug Designation in the US for Treatment of Adrenal Insufficiency
- DuoCort Hosts Adrenal Insufficiency Symposium at the 10th European Congress of Endocrinology
- DuoCort completes enrolment for pivotal phase II-III adrenal insufficiency trial
- DuoCort announces Phase I data presentation at the European Congress of Endocrinology
- DuoCort awarded 3.4 MSEK by VINNOVA
- DuoCort gets EU orphan drug designation
- News in Swedish
- DuoCort Pharmas särläkemedel Plenadren® får marknadsgodkännande i EU för behandling av binjurebarksvikt
- Läkemedelsföretaget DuoCort gör storaffär
- GP: "Nytt läkemedel snart i mål"
- Plenadren® får positiv bedömning av CHMP
- DuoCort Pharma och Clinigen ingår avtal för distribution vid licensförskrivning av Plenadren
- DuoCort Pharma och Recipharm påbörjar innovativt samarbete
- Bättre livskvalitet med ny orphan drug för Addisons sjukdom
- DuoCort ansöker om europeiskt marknadsgodkännande för sin orphan drug
- News in English